Section 3 of 6
Product information and disease description
335 evidence topics · 114 sources
Product description
Phase of product development
Summary: development status as of September 2026
The BIM-IOL System is investigational and not approved in any jurisdiction. Two identical registrational phase 3 trials (SGP-005, Rhine, NCT07218783; SGP-006, Rhone, NCT07218796) compare the 78 mcg system with a commercial monofocal IOL plus twice-daily timolol 0.5%; each plans to enroll approximately 400 participants at 45 sites. The sponsor expects enrollment to complete in 2027, 12-month data in 2028, 24-month data in 2029, and submission of a 505(b)(2) NDA in 2028. The sponsor expects regulation as a drug-led, drug-device combination product with CDER as lead center and states no current plans to seek device premarket approval. No FDA expedited-program designation was identified in the sponsor's SEC filings. SpyGlass Pharma completed its initial public offering on Nasdaq (ticker SGP) in February 2026 with gross proceeds of $172.5 million.
Investigational status and registrational phase 3 program
Phase 3 registry records
| Field | SGP-005 |
|---|---|
| Brief title | “Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)” |
| Start date | “2025-10-15” |
| Estimated primary completion date | “2029-03-31” |
| Estimated enrollment | “400” |
| Field | SGP-006 |
|---|---|
| Brief title | “Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)” |
| Estimated primary completion date | “2029-05-31” |
| Estimated enrollment | “400” |
FDA regulatory pathway: 505(b)(2) NDA
Drug-device combination product: lead center and device component
Investigational new drug application
Initial public offering and SEC reporting status
Patents and licensed intellectual property
Patent limitation: active ingredient in the public domain
Regulatory exclusivity potentially applicable to a non-NCE product
Related product in development: BIM-DRS for pseudophakic participants
| Field | Quoted record |
|---|---|
| Brief title | “Evaluation of the Safety, Efficacy, Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Diagnosed With Open Angle Glaucoma or Ocular Hypertension” |
| Estimated enrollment | “24” |
FDA fast track, breakthrough therapy, or other expedited-program designations
No evidence found.
Regulatory status: Submission planned; NDA planned for 2028
Launch
No evidence found.
Product information
Generic, brand name and therapeutic class of product
Manufacturer: SpyGlass Pharma
Product names
| Registry field | Quoted record |
|---|---|
| Intervention name | “Bimatoprost Implant System” |
| Intervention description | “Bimatoprost Implant System used in combination with the SpyGlass IOL” |
| Device intervention | “SpyGlass Intraocular Lens” |
Therapeutic class of the active ingredient
Proprietary (brand) name
No evidence found.
Dosage forms and strengths
Components: drug pads, intraocular lens, and injector
Pad material, lens specifications, and dimensions
“The studied drug delivery system consists of two silicone molded pads attached to an IOL (defined as the bimatoprost implant system). Each pad sits at the optic–haptic junction, contains a multiyear bimatoprost load, and delivers slow, continuous elution of bimatoprost with a near-zero-order delivery profile.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The SpyGlass IOL itself is a monofocal lens made of hydrophobic acrylic material with a UV inhibitor. Available powers range from 10.0 to 32.0 diopters (D). With pads equipped, the overall product measures 6 mm wide and 12.5 mm long (Fig. 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Strength selected for phase 3 (intended commercial dose)
Strengths studied in earlier trials and their correspondence
Lens optic configurations under development
Commercial packaging, storage conditions, and shelf life
No evidence found.
Average sales price and wholesale acquisition cost
BIM-IOL System price
Not applicable.
Pricing benchmark used in the sponsor's market estimate: iDose TR
Durysta wholesale acquisition cost
No evidence found.
American hospital formulary service (AHFS), or other drug classification
Pharmacologic class of bimatoprost: Lumigan labeling
AHFS classification
No evidence found.
Indication
Population studied in the phase 3 trials
Approved indication
Not applicable.
Pharmacology
Mechanism of action
Bimatoprost mechanism of action: Lumigan labeling
Delivery mechanism: diffusion from capsular-bag pads into the aqueous humor
Rationale for intraocular delivery: sponsor statement on topical penetration
Pharmacodynamics
Onset and time to maximum IOP effect of topical bimatoprost: Lumigan labeling
Onset and durability of IOP lowering: first-in-human study
“By week 1, all groups achieved mean IOP reductions exceeding 40% (p < 0.05 all). This extent of IOP control generally held stable across 2 years of follow-up, with a small uptick in IOP in the medium configuration (150 μg) cohort at year 3 (Fig. 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the aggregate sample, mean percentage IOP reduction from baseline was 36.7 ± 9.4% (p < 0.0001) by month 36.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose response: first-in-human study
“Outcomes were not significantly different between low, medium, and high concentrations of sustained release bimatoprost. One may hypothesize that higher doses would correlate with more substantive IOP-lowering. However, this did not necessarily hold true in the current sample; the greatest IOP reduction from baseline to month 36 was achieved in the 75 μg cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose response: phase 1/2 trial at 3 and 12 months
Nonclinical toxicology: 39-week single-dose rabbit study
Pharmacokinetics
In vitro release: sponsor description of three-year release
Pad elution data: in vitro release rate and aqueous humor concentrations in dogs
Pad configurations and target daily release rates described in patent filings
Systemic exposure: nonclinical toxicokinetics
Bimatoprost absorption, distribution, metabolism, and excretion: Lumigan labeling
Systemic exposure after intracameral bimatoprost: Durysta labeling
Human aqueous humor or plasma pharmacokinetics of the BIM-IOL System
No evidence found.
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
FDA-approved prescribing information for the BIM-IOL System
Not applicable.
Ocular adverse events: phase 1/2 trial at 3 and 12 months
| Adverse event through three months | 78 mcg (n = 51) | 39 mcg (n = 23) | Control (n = 30) |
|---|---|---|---|
| Iritis | “4 (7.8)” | “1 (4.3)” | “1 (3.3)” |
| Corneal edema | “3 (5.9)” | “2 (8.7)” | “1 (3.3)” |
| Eye inflammation | “3 (5.9)” | “0” | “0” |
| Visual impairment (i.e., halos) | “2 (3.9)” | “0” | “0” |
| Dry eye | “0” | “4 (17.4)” | “1 (3.3)” |
| Visual acuity reduced (BCDVA loss ≥ 10 letters) | “2 (3.9)” | “2 (8.7)” | “2 (6.7)” |
| Meibomian gland dysfunction | “4 (7.8)” | “0” | “2 (6.7)” |
Corneal endothelial cell loss: phase 1/2 trial
Adverse events and implant stability through 36 months: first-in-human study
“There were no serious implant-related adverse events. The most common events were dry eye (21.7%), transient vision decrease (13.0%), and subconjunctival hemorrhage (8.7%). All implants remained in the capsular bag.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no cases of prostaglandin-associated periorbitopathy, no abnormal eyelash growth, and no cases of iris hyperpigmentation. There were no IOL dislocations, bimatoprost drug pad displacements, explantations, or reports of clinically significant posterior capsule opacification.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was a reduction from a baseline of 2308 ± 223 cells/mm2 to 2068 ± 374 cells/mm2 (− 10.4%) by month 6 and 2013 ± 407 cells/mm2 (− 12.8%) by month 12.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Warnings and precautions for topical bimatoprost: Lumigan labeling
Contraindications and warnings for intracameral bimatoprost: Durysta labeling
Sponsor-disclosed risk: future identification of bimatoprost adverse effects
Procedures for implant removal or exchange
No evidence found.
Special populations
Age of participants: eligibility and baseline
| Study | Quoted minimum age |
|---|---|
| SGP-005 phase 3 | “22 Years” |
“Mean age was 70.5 ± 9.6 years, with a near-equal gender ratio. All subjects were of Hispanic/Latino ethnicity and Caucasian race, and all were diagnosed with primary open-angle glaucoma (POAG) with a mean vertical cup-to-disc ratio of 0.6 ± 0.2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ocular comorbidities excluded from the first-in-human study
“Central corneal endothelial cell count < 2000 cells/mm2 by specular microscopy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Diabetic retinopathy or diabetic maculopathy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Any pathology of the zonules including evidence of zonular weakness, zonular instability, zonular damage, or coloboma effecting zonules” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pregnancy, lactation, pediatric, and geriatric use of bimatoprost: Lumigan labeling
Pregnancy, lactation, and pediatric use of intracameral bimatoprost: Durysta labeling
Generalizability of first-in-human data to other populations
Renal or hepatic impairment
No evidence found.
Drug/Drug, drug/disease interactions
Effects of other drugs on BIM-IOL System
Additional prostaglandin analog dosing: Lumigan labeling
Protocol medication exclusions: first-in-human study
“Any medication in the fellow eye that would impact IOP in the study eye” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Use of tamsulosin or silodosin (e.g., Flomax, Flomaxtra, Rapaflo) or similar medications” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical drug interaction studies
No evidence found.
Effects of BIM-IOL System on other drugs
Bimatoprost metabolism and systemic exposure: Lumigan labeling
Clinical drug interaction studies
No evidence found.
Dosing and administration
Dosage
Intended commercial dose and duration
Dose levels studied: first-in-human study
Proposed labeled dosing and retreatment interval
No evidence found.
Administration
Surgical implantation procedure
“In use, the drug pads are attached to the SpyGlass IOL by either the sterile technician or the surgeon with the assistance of the primary packaging. Once attached, the system is loaded into a commercially available IOL inserter. Next, the tip of the inserter is placed into the primary incision. Lastly, the system is advanced through the inserter into the capsular bag and implanted in the same manner as other marketed C-loop haptic IOLs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lens power range and single-surgeon experience: first-in-human study
“Procedures were performed by a single ophthalmologist; given that cataract surgery approaches vary, other operators may realize challenges with a new product.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“this study was not designed to explore the frequencies at which target vision was achieved without correction. The lens selection was limited to the + 19.0 to + 25.0 D range.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Procedure coding: add-on Category III CPT code
Access and distribution
Current access: investigational use in clinical trials only
Anticipated buy-and-bill model, Medicare Part B coverage, and J-code
Coding risk: miscellaneous J-codes before a product-specific code
Manufacturing and supply chain
Planned commercial field force
Expanded access program, specialty distribution, and REMS
No evidence found.
Co-prescribed/Concomitant therapies
Postoperative regimen: first-in-human study
“The postoperative regimen included a weekly taper of topical steroid/antibiotic combination from Q4H to Q6H to Q8H over a 3-week period. IOP-lowering drops were not reintroduced unless clinically necessary.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Preoperative washout of IOP-lowering medications
Adjunctive topical IOP-lowering medication after implantation
“All 16 subjects in the 75 μg and 150 μg cohorts remained off glaucoma drops through month 36. A single subject in the 300 μg arm required reintroduction of a topical IOP-lowering medication at month 30.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Concomitant topical ocular therapy: Lumigan labeling
Combination with MIGS, SLT, or later angle procedures
Clinical data on use combined with MIGS or SLT
No evidence found.
Effect of BIM-IOL System on quality measures
MIPS Quality ID 141: POAG reduction of IOP by 20% or plan of care
Proportion of eyes with IOP reduction of more than 20%: first-in-human study
MIPS Quality ID 191: visual acuity after cataract surgery, with glaucoma exclusion
| Table 1 - Significant Ocular Conditions | Quoted entry |
|---|---|
| Condition listed | “Glaucoma” |
MIPS Quality ID 389: refractive outcome after cataract surgery
HEDIS measures for glaucoma and BIM-IOL System-specific effect on quality measures
No evidence found.
Product comparison
Summary
No head-to-head clinical comparison of the BIM-IOL System with Durysta, iDose TR, topical bimatoprost, SLT, or MIGS has been reported. The phase 3 comparator is a commercial monofocal IOL plus twice-daily timolol 0.5%, the same active control used in the registrational trials of Durysta and iDose TR. Product characteristics differ by labeling and sponsor disclosures: Durysta is a biodegradable 10 mcg intracameral bimatoprost implant limited to a single implant per eye; iDose TR is a nonbiodegradable titanium implant containing 75 mcg travoprost, anchored in the sclera through the trabecular meshwork using gonioscopy, with readministration permitted no more than once per year subject to corneal endothelial cell density criteria; topical Lumigan 0.01% is dosed once daily. The BIM-IOL System places two nonbioerodible pads containing 78 mcg bimatoprost (phase 3 dose) on an IOL in the capsular bag during cataract surgery, with a sponsor-stated design duration of three years, and is therefore limited to eyes undergoing cataract surgery; retreatment would require the separate BIM-DRS in development. Reported conjunctival hyperemia rates were 31% with Lumigan 0.01% and 27% with Durysta in their labeling, compared with 1 of 23 participants (4.3%) in the nonrandomized BIM-IOL first-in-human study; these are cross-trial observations with different designs. The iDose TR wholesale acquisition cost announced by Glaukos is $13,950 per implant; no BIM-IOL System price has been announced.
Sustained-release glaucoma therapies: review comparison table
Single-use limitation of approved intracameral implants: review
“Currently, the two available intracameral implants are only approved by the FDA for single use due to safety issues. The travoprost implant is not degradable, and if the drug is depleted, the implant must be removed and re-administered.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Durysta: dosage form, administration limit, and efficacy versus timolol
iDose TR: dosage form, implantation, readministration, and efficacy versus timolol
Topical bimatoprost: dosing, efficacy, and conjunctival hyperemia
Cross-trial comparison with trabecular bypass MIGS: first-in-human study
“In medication-washout clinical trials of trabecular bypass devices combined with CEIOL, mean IOP reduction ranged from 31.1 to 36.9%, reduction > 20% was achieved by 75.8 to 80.0% of subjects, and medication-free rates at 1 year were 77.1 to 85% [18–22]. The currently studied drug delivery system appeared comparable in magnitude to published MIGS outcomes, although cross-trial comparisons are exploratory and hypothesis-generating only.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As with any investigation that examines a technology paired with cataract extraction, one must consider the standalone 2–4 mmHg reduction achieved by the latter in glaucoma populations [26, 27]. We did not include a CEIOL-only group comparator, which should be considered in future trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Head-to-head comparison of the BIM-IOL System with Durysta, iDose TR, SLT, or MIGS
No evidence found.
Place of product in therapy
Disease description
Definition and etiology
Definition: primary open-angle glaucoma
“The glaucomas are a group of progressive optic neuropathies characterized by degeneration of retinal ganglion cells and resulting changes in the optic nerve head. Loss of ganglion cells is related to the level of intraocular pressure, but other factors may also play a role. Reduction of intraocular pressure is the only proven method to treat the disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Definition: ocular hypertension and primary open-angle glaucoma suspect
Classification: open-angle and angle-closure glaucoma
“Glaucomas can be classified into 2 broad categories: open-angle glaucoma and angle-closure glaucoma. In the United States, more than 80% of cases are open-angle glaucoma; however, angle-closure glaucoma is responsible for a disproportionate number of patients with severe vision loss.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Etiology and risk factors
“Glaucoma is a chronic progressive optic neuropathy, characterized by damage to the optic nerve and retinal nerve fiber layer, that can lead to permanent loss of peripheral or central vision. Intraocular pressure is the only known modifiable risk factor. Other important risk factors include older age, nonwhite race, and a family history of glaucoma. Several systemic medical conditions and medications including corticosteroids, anticholinergics, certain antidepressants, and topiramate may predispose patients to glaucoma.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Risk factors for primary open-angle glaucoma-the most common form of glaucoma-include older age, elevated intraocular pressure, sub-Saharan African ethnic origin, positive family history, and high myopia.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Etiology: genetic contribution
Baseline predictors of conversion from ocular hypertension to primary open-angle glaucoma
“In multivariate analyses, baseline factors that predicted the development of POAG included older age, larger vertical or horizontal cup-disc ratio, higher intraocular pressure, greater pattern standard deviation, and thinner central corneal measurement.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Central corneal thickness was found to be a powerful predictor for the development of POAG.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Magnitude of risk by age, ancestry, and refractive error
“In a meta-analysis of population-based studies, the odds ratio for primary open-angle glaucoma was 1·73 (95% CI 1·63–1·82) for each decade increase in age beyond 40 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Across all ethnic origins, individuals of African ancestry had the highest prevalence of glaucoma (6·11%, 95% CI 3·83–9·13) and primary open-angle glaucoma (5·40%, 3·17–8·27)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“High myopia with a myopic refractive error of roughly more than –8 diopters was another strong risk factor for glaucoma.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Heritability and the proportion of Mendelian disease
“Glaucoma, a highly heritable complex human disease, has an estimated heritability of 70%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Approximately 5% of primary OAG is Mendelian, with autosomal-dominant inheritance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Familial risk among siblings of affected individuals
“Siblings of affected individuals have nearly an eight times increased risk of primary open-angle glaucoma and a five times increased risk of angle closure when compared with siblings of unaffected individuals.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Epidemiology
Incidence of Open-angle glaucoma or ocular hypertension
Global incidence: systematic review and meta-analysis of prospective studies
“A total of 9050 articles were identified in literature search, and 50 articles provided incidence data of glaucoma subtypes. In 2022, the global incidence rate of POAG was 23.46 (95% confidence interval (CI) = 15.68-32.91) per 10 000 person-years among 40-79 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The pooled ACI of POAG was 0.21% (95% CI = 0.13%-0.30%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States incidence: Medicare fee-for-service beneficiaries, 2017 to 2021
United States incidence: Olmsted County, Minnesota
“The overall age- and gender-adjusted annual incidence rate of OAG in a predominantly Caucasian population is conservatively estimated to be 14.5 per 100,000 population. The rates increased with age from 1.6 in the fourth decade of life to 94.3 in the eighth decade.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States incidence of open-angle glaucoma and ocular hypertension: Los Angeles Latino Eye Study
“Among the 3939 participants (mean age, 54.7 ± 10.5 years) with complete data for a diagnosis of glaucoma at both baseline and follow-up examination, incident OAG at the 4-year follow-up was identified in 87 persons (4-year incidence rate, 2.3%; 95% confidence interval, 1.8% to 2.8%). Incident OHT at the 4-year follow-up was identified in 124 persons (4-year incidence rate, 3.5%; 95% confidence interval, 2.9% to 4.1%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Incidence of primary open-angle glaucoma among individuals with ocular hypertension: Ocular Hypertension Treatment Study, 20-year follow-up
“A total of 1636 individuals (mean [SD] age, 55.4 [9.6] years; 931 women [56.9%]; 1138 White participants [69.6%]; 407 Black/African American participants [24.9%]) were randomized in phase 1 of the clinical trial. Of those, 483 participants (29.5%) developed POAG in 1 or both eyes (unadjusted incidence). After adjusting for exposure time, the 20-year cumulative incidence of POAG in 1 or both eyes was 45.6% (95% CI, 42.3%-48.8%) among all participants, 49.3% (95% CI, 44.5%-53.8%) among participants in the observation group, and 41.9% (95% CI, 37.2%-46.3%) among participants in the medication group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of Open-angle glaucoma or ocular hypertension
Global prevalence: systematic review and meta-analysis with projections to 2040
“The global prevalence of glaucoma for population aged 40-80 years is 3.54% (95% CrI, 2.09-5.82). The prevalence of POAG is highest in Africa (4.20%; 95% CrI, 2.08-7.35), and the prevalence of PACG is highest in Asia (1.09%; 95% CrI, 0.43-2.32). In 2013, the number of people (aged 40-80 years) with glaucoma worldwide was estimated to be 64.3 million, increasing to 76.0 million in 2020 and 111.8 million in 2040.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Global prevalence of open-angle glaucoma: updated meta-analysis with projections to 2060
“Global OAG prevalence (≥40 years) is expected to rise from 2.8% (95% CI, 2.6%-3.0%) in 2024 to 3.5% (95% CI, 3.2%-3.8%) by 2060, with the affected population increasing from 80.5 (95% CI, 75.4-85.6) million to 186.6 (95% CI, 174.3-199.0) million.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States prevalence in 2022: CDC Vision and Eye Health Surveillance System estimates
“For 2022, an estimated 4.22 million people (95% uncertainty interval [UI], 3.46 million to 5.23 million) in the US were living with glaucoma, with a prevalence of 1.62% (UI, 1.33%-2.00%) among people 18 years or older and 2.56% (UI, 2.10%-3.16%) among people 40 years or older. An estimated 1.49 million people (UI, 1.17 million to 1.90 million) were living with vision-affecting glaucoma, with a prevalence of 0.57% (UI, 0.45%-0.73%) among people 18 years or older and 0.91% (UI, 0.71%-1.16%) among people 40 years or older.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Black adults had a prevalence of 3.15% (UI, 2.32%-4.09%) compared with 1.42% (UI, 1.10%-1.85%) among White adults; adults in the Hispanic and all other racial and ethnic categories combined had a prevalence of 1.56% (UI, 1.13%-2.06%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States prevalence: Medicare fee-for-service beneficiaries
United States prevalence and undiagnosed disease: National Health and Nutrition Examination Survey, 2005 to 2008
“The estimated overall prevalence of glaucoma in the US civilian, noninstitutionalized population 40 years of age and older was 2.1% (95% confidence interval [CI], 1.7%-2.6%). Glaucoma affected 2.9 million individuals, including 1.4 million women; 1.5 million men; 2.3 million people 60 years of age and older; and 0.9 million blacks, Mexican Americans, and people of other races.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Over half of participants with glaucoma were unaware that they had the disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Prevalence of undiagnosed glaucoma was 2.9%, increasing with age to 6.6% of the population over 70 years old. Among those with glaucoma, 78% were previously undiagnosed and untreated.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Approximately 2.4 million persons in the US have undetected and untreated glaucoma.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Racial and ethnic differences in prevalence
Prevalence of ocular hypertension in the United States
Coexisting glaucoma and cataract: prevalence among Medicare cataract surgery patients
“133,896 records of 82,246 CMS FFS claims were included in the analysis. The average patient age was 73.8, and 58.2% were females. The cataract surgery setting was ASC (71.3%) followed by HOPD (27.6%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common comorbidities included diabetes (28.6%), glaucoma (22.1%), and macular degeneration (21.7%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Coexisting glaucoma and cataract: manufacturer estimate of United States cataract surgeries in patients with glaucoma or ocular hypertension
Contribution of population aging and rising myopia to the projected increase
“Compared to 2024, the global OAG population in 2060 is projected to increase by 106.2 million (131.9%). Accounting only for the aging and demographic effect, the increase is estimated to be 77.3 million (72.8% of the total increase), with the remaining 28.9 million (27.2%) attributable to the rising prevalence of myopia.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The global prevalence of OAG is projected to rise from 2.8% to 3.5% between 2024 and 2060, with an estimated 193 million cases anticipated by 2060.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Evidence base and stated limitations of the 2060 projection
“After exclusion, 57 studies published between 1991 and 2023 were included and the data were extracted.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“First, we did not stratify by the degree of myopia; instead, we used a single risk ratio for overall myopia, given the dose-response relationship between myopia severity and OAG.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Fourth, the current estimation of OAG prevalence among the 20–39-year age group was highly approximate, as it relied on only 3 studies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Relative frequency of open-angle and angle-closure glaucoma and differences by sex and ancestry
“Primary open-angle glaucoma, with a global prevalence of about 3·1%, was six times more common than primary angle-closure glaucoma, which had a global prevalence of about 0·5%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“With respect to primary open-angle glaucoma, men were more likely than women to have this disorder (odds ratio [OR] 1·36), as were people of African ancestry compared with people of European ancestry (OR 2·80)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Natural history, survival, and mortality
Conversion from ocular hypertension to primary open-angle glaucoma: Ocular Hypertension Treatment Study, 5-year results
“During the course of the study, the mean +/- SD reduction in IOP in the medication group was 22.5% +/- 9.9%. The IOP declined by 4.0% +/- 11.6% in the observation group. At 60 months, the cumulative probability of developing POAG was 4.4% in the medication group and 9.5% in the observation group (hazard ratio, 0.40; 95% confidence interval, 0.27-0.59; P<.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Conversion from ocular hypertension to primary open-angle glaucoma: Ocular Hypertension Treatment Study, 20-year results
“The 20-year cumulative incidence of POAG was 55.2% (95% CI, 47.9%-61.5%) among Black/African American participants and 42.7% (95% CI, 38.9%-46.3%) among participants of other races. The 20-year cumulative incidence for visual field loss was 25.2% (95% CI, 22.5%-27.8%). Using a 5-factor baseline model, the cumulative incidence of POAG among participants in the low-, medium-, and high-risk tertiles was 31.7% (95% CI, 26.4%-36.6%), 47.6% (95% CI, 41.6%-53.0%), and 59.8% (95% CI, 53.1%-65.5%), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Progression of untreated and treated early glaucoma: Early Manifest Glaucoma Trial
“After a median follow-up period of 6 years (range, 51-102 months), retention was excellent, with only 6 patients lost to follow-up for reasons other than death. On average, treatment reduced the IOP by 5.1 mm Hg or 25%, a reduction maintained throughout follow-up. Progression was less frequent in the treatment group (58/129; 45%) than in controls (78/126; 62%) (P =.007) and occurred significantly later in treated patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“After 6 years, 53% of patients progressed. In multivariate analyses, progression risk was halved by treatment (HR = 0.50; 95% CI, 0.35-0.71).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Progression risk decreased by about 10% with each millimeter of mercury of IOP reduction from baseline to the first follow-up visit (HR = 0.90 per millimeter of mercury decrease; 95% CI, 0.86-0.94).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Lifetime risk of blindness in treated open-angle glaucoma: Sweden
“Five hundred and ninety-two patients were included. At the time of the last visit 250 patients (42.2%) had at least 1 blind eye because of glaucoma, while 97 patients (16.4%) were bilaterally blind, and 12 patients (0.5%) had low vision. Median time with a glaucoma diagnosis was 12 years (<1-29), median age when developing bilateral blindness was 86 years, and median duration of bilateral blindness was 2 years (<1-13). The cumulative incidences of blindness in at least 1 eye and bilateral blindness from glaucoma were 26.5% and 5.5%, respectively, after 10 years, and 38.1% and 13.5% at 20 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Probability of blindness in treated open-angle glaucoma: Olmsted County, Minnesota
“Probability of glaucoma-related blindness in at least one eye at 20 years decreased from 25.8 % (95% Confidence interval [CI]: 18.5–32.5) for subjects diagnosed in 1965–1980, to 13.5% (95% CI: 8.8–17.9) for subjects diagnosed in 1981–2000 (P=0.01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, a significant proportion of patients still progress to blindness despite recent diagnostic and therapeutic advancements.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 20-years' follow-up, the Kaplan-Meier cumulative probability of glaucoma-related blindness in at least one eye was estimated to be 27% (95% confidence interval, 20%-33%), and for both eyes, it was estimated to be 9% (95% confidence interval, 5%-14%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Global blindness and vision impairment attributable to glaucoma
“Globally, in 2020, 3.61 million people were blind and nearly 4.14 million were visually impaired by glaucoma. Glaucoma accounted for 8.39% (95% uncertainty intervals [UIs]: 6.54, 10.29) of all blindness and 1.41% (95% UI: 1.10, 1.75) of all MSVI. Regionally, the highest proportion of blindness relating to glaucoma was found in high-income countries (26.12% [95% UI: 20.72, 32.09]), while the region with the highest age-standardized prevalence of glaucoma-related blindness and MSVI was Sub-Saharan Africa.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The leading global causes of blindness in those aged 50 years and older in 2020 were cataract (15·2 million cases [9% IU 12·7-18·0]), followed by glaucoma (3·6 million cases [2·8-4·4]), undercorrected refractive error (2·3 million cases [1·8-2·8]), age-related macular degeneration (1·8 million cases [1·3-2·4]), and diabetic retinopathy (0·86 million cases [0·59-1·23]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Disease severity at detection: population screening
“Among the screened subjects, who were 77.5% of all invited subjects, a total of 406 subjects (1.23%) were identified with previously undetected glaucoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most eyes had early (35%) or moderate (31%) glaucomatous visual field defects, but 134 subjects (33%) had advanced visual field loss in at least one eye. No subject was blind in both eyes, but 3.4% of the newly diagnosed patients were unilaterally blind due to glaucoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: systematic review and meta-analysis of prospective studies
“Seven articles were included. The pooled ACM of POAG was 3.42% (95% confidence interval [CI] 1.70%-5.58%). The mortality rate of POAG was reported in one study as 6.1 (95% CI 5.5-6.7) per 1000 person-years. A significant association between POAG and mortality was observed in the pooled unadjusted relative mortality risk estimates (HR 2.14, 95% CI 1.32-3.47). Fully adjusted relative mortality risk estimates did not show a significant association with mortality (HR 1.13, 95% CI 0.91-1.40).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Follow-up duration and form of the first glaucoma endpoint in the Ocular Hypertension Treatment Study
“The median duration of follow-up was 72 months for African American participants and 78 months for other participants. Of the expected follow-up visits, 90% were completed during the study, and the visit completion rate did not differ by randomization group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Approximately 55% (69 of 125) of the initial POAG endpoints involved optic disc deterioration in the absence of visual field abnormalities meeting study criteria for a visual field endpoint.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Vision impairment and blindness after 14 years in the Early Manifest Glaucoma Trial
“The number of analyzed subjects was 128 in the treatment group and 123 in the initially untreated control group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean age at baseline was nearly identical in both study arms, but the mean age at study end was 1 year higher and mean follow-up time was more than 1 year longer in the control group (14.8 years) than in the treatment group (13.7 years)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This was true both for VI in at least one eye and bilateral impairment 19.5% vs 18.7% and 4.7% vs 3.3%, respectively, as well as for unilateral and bilateral blindness, 12.5% vs 7.3% and 3.1% vs 2.4%, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“More than half of the subjects died during the study period: 68 (53%) in the treated group and 65 (53%) in the control group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Derivation and evidence base of the pooled annual cumulative mortality estimate
“Cumulative mortality was defined as the number of deaths during the follow-up period over the total glaucoma individuals at baseline.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Random-effects meta-analysis was conducted on the remaining four articles with available follow-up period.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The included articles did not cover the regions of Africa and the Eastern Mediterranean, with the majority concentrated in high-income countries or regions (71.4%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Effect of comorbidity adjustment on the association between glaucoma and mortality
“Another article based on data from Finnish social insurance found a cumulative mortality of 17.2% for POAG in Finland from June 2004 to January 2013” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This difference may be partly explained by adjustment for comorbidities and differences in covariate selection across studies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Given the impact of these comorbidities on mortality, we speculate that the observed association may be influenced by underlying health status and comorbidity burden rather than glaucoma itself” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pathophysiology
Aqueous humor dynamics and intraocular pressure
“Although the pathogenesis of glaucoma is not fully understood, the level of intraocular pressure is related to retinal ganglion cell death.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with open-angle glaucoma, there is increased resistance to aqueous outflow through the trabecular meshwork.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mechanical stress at the lamina cribrosa and axonal transport
“The sclera is perforated at the lamina where the optic nerve fibers (retinal ganglion cell axons) exit the eye. The lamina is the weakest point in the wall of the pressurized eye. Intraocular pressure–induced stress and strain may result in compression, deformation, and remodeling of the lamina cribrosa with consequent mechanical axonal damage and disruption of axonal transport” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pressure-independent mechanisms
“Glaucomatous optic neuropathy can occur in individuals with intraocular pressures within the normal range. In such patients, there may be an abnormally low cerebrospinal fluid pressure in the optic nerve subarachnoid space resulting in a large pressure gradient across the lamina.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Impaired microcirculation, altered immunity, excitotoxicity, and oxidative stress may also cause glaucoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pattern of retinal ganglion cell loss and visual field damage
“Retinal ganglion cell loss causes progressive deterioration of visual fields, which usually begins in the midperiphery and may progress in a centripetal manner until there remains only a central or peripheral island of vision.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis
Guideline: comprehensive initial glaucoma evaluation
Guideline: diagnostic tests
| Diagnostic test | Quoted record |
|---|---|
| Corneal thickness | “CCT measurement” |
| Corneal biomechanics | “Corneal hysteresis measurement” |
| Visual function | “Visual field evaluation” |
| Structural imaging | “ONH, circumpapillary RNFL, and macular ganglion cell layer imaging” |
Structural and functional criteria and limits of early detection
“With retinal ganglion cell death and optic nerve fiber loss in glaucoma, characteristic changes in the appearance of the optic nerve head and retinal nerve fiber layer occur.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because there is no single perfect reference standard for establishing the diagnosis of glaucoma, early diagnosis can be challenging.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Presence of characteristic visual field defects can confirm the diagnosis, but as many as 30% to 50% of retinal ganglion cells may be lost before defects are detectable by standard visual field testing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These techniques, including confocal scanning laser ophthalmoscopy, scanning laser polarimetry, and optical coherence tomography, have improved the identification of early disease and also enhanced the observation of progressive optic nerve fiber loss over time” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Intraocular pressure alone does not establish the diagnosis
“Although elevated intraocular pressure is a very consistent risk factor for the presence of glaucoma, several population-based studies found intraocular pressure was lower than 22 mm Hg in 25% to 50% of individuals with glaucoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnostic and monitoring tests in clinical practice
“Diagnostic testing to assess for glaucoma and to monitor for disease progression includes measurement of intraocular pressure, perimetry, and optical coherence tomography.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Glaucoma is diagnosed using ophthalmoscopy, tonometry, and perimetry.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Test variability and the number of examinations needed to detect deterioration
“Perimetry describes the subjective psychophysical defect as experienced by the patient, but it has fairly high intervisit variability, so at least three perimetric examinations could be necessary to detect visual-field deterioration reliably.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“One measurement of intraocular pressure has a low sensitivity to detect glaucoma under screening conditions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Proportion of cases undiagnosed and the case against population-wide screening
“A large proportion (50–90%) of patients with glaucoma remain undiagnosed in developed, developing, and underdeveloped regions of the world.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Because of the fairly low prevalence of glaucoma (about 3·5% in individuals aged 40 years or older), and since diagnostic measures with sufficient precision are not yet available, general screening for glaucoma would result in an unacceptably high number of false-positive diagnoses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Clinical presentation - signs and symptoms
Early disease: absence of symptoms
Visual symptoms: peripheral vision loss and associated complaints
“Symptoms more common among glaucoma patients compared with glaucoma suspects included better vision in 1 eye, blurry vision, glare, sensitivity to light, cloudy vision, missing patches of vision, and little peripheral vision. Worse severity ratings for the symptom "little peripheral vision" explained the most variance in VF damage (43%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Visual symptoms: distinguishing glaucoma from cataract
“Compared with cataract patients, glaucoma patients were more likely to report poor peripheral vision (OR 7.24, 95% CI: 2.53-20.72) and missing patches (OR 4.91, 95% CI: 1.52-15.84), but less likely to report worsening vision (OR 0.08, 95% CI 0.03-0.22), explaining 33% of the variance in diagnosis (ie, glaucoma vs. cataract).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Asking about visual symptoms may serve as a useful diagnostic adjunct and inform decision-making, for example, in glaucoma patients considering cataract surgery.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Functional symptoms: late-stage vision loss and daily activities
“Glaucoma progresses without causing symptoms until the disease is advanced with substantial amounts of neural damage. When symptoms do occur, the disease results in vision loss with concomitant reduction in quality of life and the ability to perform daily activities, such as driving.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Signs: optic nerve and retinal nerve fiber layer findings
Psychological symptoms: depression
“Thirty-eight studies including 21,705 patients with glaucoma contributed to the single-group prevalence meta-analysis; pooled depression prevalence was 26.03% (95% CI, 21.10%-31.64%; prediction interval 5.98%-66.04%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“GRADE certainty was very low for the comparative, prevalence, and longitudinal evidence domains.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term morbidity
Falls and fractures: population-based cohort in England
“Compared with comparators, there was an increased risk of falls in those with cataract (adjusted hazard ratio [HR], 1.36; 95% CI, 1.35-1.38), AMD (HR, 1.25; 95% CI, 1.23-1.27), and glaucoma (HR, 1.38; 95% CI, 1.35-1.41). Likewise for fractures, there were increased risks in all eye diseases, with an HR of 1.28 (95% CI, 1.27-1.30) in the cataract cohort, an HR of 1.18 (95% CI, 1.15-1.21) for AMD, and an HR of 1.31 (95% CI, 1.27-1.35) for glaucoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Falls by glaucoma severity: United States clinic cohort
“Of the glaucoma participants, 36% reported at least one fall in the prior 12 months compared to 20% of controls (adjusted odds ratio [OR], 2.7; 95% CI, 1.18–6.17; p=0.018). Compared to controls, the mild glaucoma group trended towards a higher fall risk (adjusted OR, 2.43; 95% CI, 0.97–6.08; p=0.059) and the advanced group had the highest fall risk (adjusted OR, 7.97; 95% CI, 2.44–26.07; p=0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Falls or fractures by severity: United States claims analysis
Driving: motor vehicle collisions
“over six times more likely to have been involved in one or more MVCs in the previous 5 years (OR(adjusted) = 6.62; 95% CI, 1.40-31.23), and more likely to have been at fault (OR(adjusted) = 12.44; 95% CI, 1.08-143.99).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Visual disability and activities of daily living
Vision-affecting glaucoma in the United States
“An estimated 1.49 million people (UI, 1.17 million to 1.90 million) were living with vision-affecting glaucoma, with a prevalence of 0.57% (UI, 0.45%-0.73%) among people 18 years or older and 0.91% (UI, 0.71%-1.16%) among people 40 years or older.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden of Open-angle glaucoma or ocular hypertension
Humanistic burden and health-related quality of life
Guideline statement: quality of life across disease stages
Vision-related quality of life by visual field loss: Ocular Hypertension Treatment Study, 20-year follow-up
“Of 1636 participants originally enrolled in the OHTS, 679 (42%) completed the 20-year examination and VRQoL surveys.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (SD) Rasch-calibrated total VFQ scores were 72.5 (13.4) in the no POAG group (control) vs 72.7 (13.8) in the unilateral disc POAG group (difference, 0.17; 95% CI, -3.17 to 3.41; P = .92), 73.4 (14.0) in the bilateral disc POAG group (difference, 0.92; 95% CI, -2.93 to 4.77; P = .64), 69.2 (14.5) in the unilateral VF POAG group (difference, 3.33; 95% CI, -6.38 to -0.27; P = .03), and 58.5 (16.9) in the bilateral VF POAG group (difference, -13.96; 95% CI, -17.73 to -10.19; P<.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vision-related quality of life and visual impairment: Early Manifest Glaucoma Trial, 20-year follow-up
“NEI VFQ-25 scores were significantly higher for patients with no visual impairment (mean 73 ± 22) than for visually impaired patients (mean 31 ± 15, p < 0.001). VFI worse than 50% or MD worse than -18 dB was significantly associated with low VRQOL scores (p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life by visual field loss: Los Angeles Latino Eye Study
“A trend of worse NEI-VFQ-25 scores for most subscales was observed with worse VF loss (using both monocular and calculated binocular data). Open-angle glaucoma participants with VF loss had lower scores than participants with no VF loss. This association was also present in participants who were previously undiagnosed and untreated for OAG (N = 160). Participants with any central VF loss had lower NEI-VFQ-25 scores than those with unilateral or bilateral peripheral VF loss. There was no significant impact of severity or location of VF loss on SF-12 scores.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Psychological burden of diagnosis and treatment
“The disease itself as well as the medical or surgical treatment can have an enormous impact on a patient's QoL. Even the mere diagnosis of a chronic, irreversible, potentially blinding disorder can adversely affect the patient's sense of well-being and QoL by eliciting significant anxiety.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sixteen studies including 14,030 glaucoma participants and 4,472,723 controls contributed to the primary odds ratio meta-analysis. Glaucoma was associated with higher odds of depression (OR, 2.80; 95% CI, 1.66-4.74; I 2 = 95.95%; approximate prediction interval 0.32-24.47).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Falls, fear of falling, and activity avoidance
“A greater risk of a high fear of falling and high avoidance of at-risk activities occurred at the moderate stage of glaucoma compared to controls (adjusted OR, 4.66; 95% CI, 1.24–17.49; p=0.023 and adjusted OR, 4.49; 95% CI, 1.34–15.05; p=0.015, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
United States incremental health care expenditures: Medical Expenditure Panel Survey, 2016 to 2018
“After 1:3 propensity matching for sociodemographics and the Charlson Comorbidity Index, this study analyzed 1521 glaucoma patients (mean expenditures: $13,585.68±1367.03) and 4563 patients without glaucoma (mean expenditures: $12,048.92±782.49).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Controlling for comorbidities and socioeconomic factors, propensity-matched glaucoma patients incur an annual incremental health care burden of $1863.17 (95% confidence interval, 393.44-3117.23, P=0.013), translating into an additional $9.2 billion in population-level US health care expenditures. By health care service sector, the expenditure ratio for health care expenditures was higher for prescription medications (expenditure ratio=1.20, 95% confidence interval, 1.02-1.42, P=0.031).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States costs by disease severity: commercial claims analysis
“One hundred seventy-seven thousand three hundred fifty-two OHT and OAG patients were identified (67.8% with OAG). Open-angle glaucoma patients showed higher eye-related outpatient costs than OHT patients (median, $516 [interquartile range (IQR), $323-$898] vs. $344 [IQR, $197-$617], respectively). Patients with severe OAG showed higher eye-related outpatient costs than moderate and mild OAG patients (median, $639 [IQR, $381-$1264] vs. $546 [IQR, $345-$950] vs. $476 [IQR, $304-$765], respectively; P < 0.0001), as well as higher glaucoma-related pharmacy costs (median, $493 [IQR, $122-$1457] vs. $244 [IQR, $84-$1113] vs. $139 [IQR, $66-$818], respectively; P < 0.0001). In adjusted analyses, disease worsening was associated with at least 2-fold higher annual eye-related outpatient costs (P < 0.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States direct costs by disease stage: multicenter medical record review
“Direct ophthalmology-related resource use, including ophthalmology visits, glaucoma surgeries, and medication use, increased as disease severity worsened. Average direct cost of treatment ranged from $623 per patient per year for glaucoma suspects or patients with early-stage disease to $2511 per patient per year for patients with end-stage disease. Medication costs composed the largest proportion of total direct cost for all stages of disease (range, 24%-61%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Guideline summary of direct and indirect costs
Medicare Part D spending on prostaglandin analogs
“In 2013, Medicare spent $733 million on prostaglandin analogs; in 2017, this increased to $1.09 billion, with $943 million (86%) spent on branded prostaglandins and $148 million (14%) spent on generics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median out-of-pocket cost of branded prostaglandins without generic equivalents was $35 (IQR = $29-$40) in 2009, $45 (IQR = $42-$101) in 2013, and $90 (IQR = $45-$159) in 2017.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Medicare Part D glaucoma medication spending per beneficiary, 2019 to 2023
“Median spending per beneficiary was $403.81 (interquartile range [IQR], $359.74-$444.73), and median spending per claim was $104.22 (IQR, $89.49-$118.41).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Utilization intensity varied minimally across socioeconomic strata (claims per beneficiary, 3.8-4.0), and neither ADI nor income was consistently associated with brand spending or claims share.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Medicare reintervention and costs after incisional glaucoma surgery
“At 1 year, 15.1% of EX-PRESS shunt patients, 11.6% of tube shunt patients, and 8.8% of trabeculectomy patients had experienced failure based on postindex procedures. By 5 years follow-up, these rates were 31.5% of EX-PRESS shunt patients, 27.1% of tube shunt patients, and 23.5% of trabeculectomy patients. Five-year rates of glaucoma reoperations were 18.3%, 14.0%, and 15.1%, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health care resource utilization: Medicare beneficiaries with glaucoma
“Among 78 526 participants with glaucoma, mean age was 79.1 years (standard deviation, 7.9 years), 60.9% were female, 78.4% were non-Hispanic White, and 13.8% met enrollment-based criteria for low-SES. Compared with White beneficiaries, Blacks had lower counts of outpatient visits (RR, 0.92; 95% confidence interval [CI], 0.90-0.93), visual field (VF) tests (RR, 0.92; 95% CI, 0.90-0.94), but more inpatient/ED encounters (RR, 2.42; 95% CI, 1.55-3.78) and surgeries (RR, 1.14; 95% CI, 1.03-1.27).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Direct and indirect costs: nationwide register study, Finland
“The annual additional total direct costs were EUR 2,660/glaucoma patient, EUR 1,769/glaucoma patient with medication, and EUR 3,979/operated glaucoma patient compared with persons without glaucoma. The respective additional total indirect costs were EUR 4,288, EUR 3,246, and EUR 12,902 per year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eye-related outpatient visits and procedure use by disease severity: United States commercial claims
“Patients with OAG appeared to have higher use of outpatient visits compared with patients with OHT only (mean, 4.2 visits [SD, 3.2 visits] vs. 3.0 visits [SD, 2.9 visits] per user, respectively). The mean number of eye-related outpatient visits increased with increasing baseline OAG severity (P < 0.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“More patients in the OAG group had a physician office visit for a laser or surgical glaucoma procedure compared with patients in the OHT group (9.4% vs. 2.2%, respectively). The proportion of patients undergoing laser or surgical glaucoma procedures increased with increasing baseline OAG severity (P < 0.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Adjusted drivers of annual eye-related outpatient costs: baseline severity and number of topical medication classes
Documented disease worsening over 12 months and associated procedure rates
“Approximately 12% of the study population had a worsening in coded severity during the 12-month follow-up period” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Open-angle glaucoma surgery or procedure rates were substantial among patients with a worsening in coded severity, with the highest observed rates among OAG patients developing severe disease (52.1% and 47.0% of patients with a worsening in coded severity from moderate to severe and mild to severe, respectively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment intensification also was observed in patients without a worsening in coded severity, ranging from 11.8% to 45.1% across baseline severity cohorts.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Aggregate United States direct medical costs and principal cost components
“Glaucoma is estimated to account for $US2.9 billion of direct medical costs among US adults annually.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In general, they have shown that increased glaucoma severity correlates with increased costs, and medication and ophthalmologist examinations account for a majority of direct costs across studied North American and European regions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cost components in end-stage glaucoma with visual rehabilitation care
“In a retrospective evaluation of resource use and costs for patients with end-stage glaucoma who were receiving visual rehabilitation care, three US centres provided 81 patient records indicating patient level billing and reimbursement for eye care visits, medications, procedures and specialized low vision and glaucoma-related services.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Visual rehabilitation services included low vision devices, assessment of daily functioning, orientation and mobility training and counselling.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Total costs for 2 years were determined to comprise 15% for visual rehabilitation, 37% for ophthalmology care and 48% for pharmaceuticals.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of Open-angle glaucoma or ocular hypertension on families
Caregiver burden in glaucoma-related blindness
“A cross-sectional study enrolled 110 adult patients with glaucoma-related blindness and their caregivers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, caregivers demonstrated higher PHQ-9 and ZBI-22 scores with rising levels of patient VI (all P < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Glaucoma-related blindness imposes significant psychological and functional burdens on patients and caregivers, with evidence of emotional contagion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Practical, financial, and emotional challenges for informal caregivers
“The study involved 11 informal caregivers, out of which 8 were females.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These included caregiving roles (basic activities of daily living, instrumental activities of daily living and emotional support), caregiving challenges (practical challenges, emotional challenges and financial challenges), coping strategies (adaptive and maladaptive coping strategies) and recommendations to clinicians (quantity of medication, review appointments and health education).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Indirect costs including informal care: vision loss in the United States
“We estimated an economic burden of VL of $134.2 billion: $98.7 billion in direct costs and $35.5 billion in indirect costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Those with VL incurred $16 838 per year in incremental burden.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Guideline statement: caregiver productivity losses
Economic impact of diagnostic testing
Guideline statement: ancillary testing as a component of direct costs
Medicare Part B payments: optical coherence tomography of the optic nerve (CPT 92133), 2024
| Field | Office and other non-facility settings | Facility settings |
|---|---|---|
| Service description | “Imaging of optic nerve” | “Imaging of optic nerve” |
| Place of service code | “O” | “F” |
| Total beneficiaries | “2353950” | “59478” |
| Total services | “2704197.1” | “67036” |
| Average submitted charge (USD) | “111.02944985” | “107.26792037” |
| Average Medicare allowed amount (USD) | “34.480219382” | “21.326738021” |
| Average Medicare payment amount (USD) | “24.047622387” | “14.822967212” |
Medicare Part B payments: extended visual field examination (CPT 92083), 2024
| Field | Office and other non-facility settings | Facility settings |
|---|---|---|
| Service description | “Exam of visual field with extended testing” | “Exam of visual field with extended testing” |
| Place of service code | “O” | “F” |
| Total beneficiaries | “2256481” | “57345” |
| Total services | “2654750” | “67503” |
| Average submitted charge (USD) | “150.1505657” | “121.66678933” |
| Average Medicare allowed amount (USD) | “62.079533207” | “26.88252611” |
| Average Medicare payment amount (USD) | “43.643536035” | “18.909151741” |
Utilization trends: visual field testing and ocular imaging in open-angle glaucoma
“169,917 individuals with OAG and 395,721 with suspected glaucoma age ≥40 enrolled in a national United States managed care network between 2001–2009.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For patients with OAG, the odds of undergoing VF testing decreased by 36% from 2001 to 2005, 12% from 2005 to 2009, and 44% from 2001 to 2009. By comparison, the odds of having OOI increased by 100% from 2001 to 2005, 24% from 2005 to 2009, and 147% from 2001 to 2009.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The probability of undergoing OOI increased from 26% in 2001 to 47% in 2009 for patients of optometrists and from 30% in 2001 to 46% in 2009 for patients of ophthalmologists.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Visual field examination costs within direct costs of glaucoma management
Geographic variation in diagnostic testing after open-angle glaucoma diagnosis
“Of the 56675 enrollees with newly-diagnosed OAG, the mean proportion of patients undergoing VF testing within two years of initial diagnosis was 74% ± 7%, ranging from as low as 51% in Rochester, MN to as high as 95% in Lancaster, PA. The mean proportion undergoing OOI was 63% ± 10% and varied from 34% in Palm Springs/Rancho Mira, CA to 85% in Charleston, SC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Approaches to treatment
Current treatment options and standard of care
Prostaglandin analogs
AAO Primary Open-Angle Glaucoma Preferred Practice Pattern: prostaglandin analogs as initial medical therapy
AAO Preferred Practice Pattern: prostaglandin analog class profile (bimatoprost, latanoprost, latanoprostene bunod, omidenepag, tafluprost, travoprost)
| Field | Quoted record |
|---|---|
| Mechanism of action | “Increase uveoscleral outflow” |
| IOP reduction | “25%–33%” |
| Potential contraindications | “Macular edema”; “History of herpetic keratitis”; “Active uveitis” |
European Glaucoma Society guidelines, 6th edition: first-choice medical treatment
NICE NG81: generic prostaglandin analog when SLT is declined, unsuitable, or insufficient
Network meta-analysis of first-line topical medications: mean IOP reduction at 3 months
“We included 114 randomized controlled trials with data from 20,275 participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean reductions (95% credible intervals) in IOP in mmHg at 3 months, ordered from the most to least effective drugs were: bimatoprost 5·61 (4·94; 6·29), latanoprost 4·85 (4·24; 5·46), travoprost 4·83 (4·12; 5·54), levobunolol 4·51 (3·85; 5·24), tafluprost 4·37 (2·94; 5·83), timolol 3·7 (3·16; 4·24), brimonidine 3·59 (2·89; 4·29), carteolol 3·44 (2·42; 4·46), levobetaxolol 2·56 (1·52; 3·62), apraclonidine 2·52 (0·94; 4·11), dorzolamide 2·49 (1·85; 3·13), brinzolamide 2·42 (1·62; 3·23), betaxolol 2·24 (1·59; 2·88), and unoprostone 1·91 (1·15; 2·67).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Bimatoprost, latanoprost, and travoprost are among the most efficacious drugs, although the within-class differences were small and may not be clinically meaningful.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
UKGTS: latanoprost versus placebo and visual field preservation
“We enrolled 516 individuals between Dec 1, 2006, and March 16, 2010.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At 24 months, mean reduction in intraocular pressure was 3·8 mm Hg (4·0) in 231 patients assessed in the latanoprost group and 0·9 mm Hg (3·8) in 230 patients assessed in the placebo group. Visual field preservation was significantly longer in the latanoprost group than in the placebo group: adjusted hazard ratio (HR) 0·44 (95% CI 0·28-0·69; p=0·0003).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Network meta-analysis: bimatoprost concentrations analyzed and efficacy of bimatoprost 0.01%
“Of the 17 bimatoprost trials included in our network, 15 evaluated bimatoprost 0·03% and two evaluated bimatoprost 0·01%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Bimatoprost 0.01% is no more effective than latanoprost or travoprost in lowering IOP at 3 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Bimatoprost, when the two concentrations (0·03% and 0·01%) are not differentiated, resulted in a statistically significant lower IOP than any other active drug except tafluprost, although the pair-wise differences in lowering IOP at 3 months among bimatoprost, latanoprost, travoprost, and tafluprost are small and may not be clinically meaningful.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of the first-line medication evidence base
“An evidence synthesis such as the network meta-analysis we have done does not overcome the underlying fact that some studies we included were at high or unclear risk of bias, had small sample size, short follow-up time and used IOP, a surrogate outcome to assess treatment effect.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Beta-adrenergic antagonists
AAO Preferred Practice Pattern: topical beta-blockers
AAO Preferred Practice Pattern: beta-blocker class profile (carteolol, levobunolol, timolol, betaxolol)
| Field | Quoted record |
|---|---|
| Mechanism of action | “Decrease aqueous production” |
| IOP reduction | “20%–25%” |
| Potential contraindications | “Chronic obstructive pulmonary disease”; “Asthma”; “CHF”; “Bradycardia”; “Hypotension” |
European Glaucoma Society guidelines: relative efficacy and combination use
NICE NG81: beta-blocker as second choice when prostaglandin analogs are not tolerated
Timolol as the active comparator in sustained-release registrational trials
Other topical intraocular pressure-lowering medication classes
AAO Preferred Practice Pattern: other classes for long-term IOP reduction
AAO Preferred Practice Pattern: expected IOP reduction by class
| Drug classification (agents) | IOP reduction |
|---|---|
| Alpha-2 adrenergic agonists (apraclonidine, brimonidine) | “20%–25%” |
| Parasympathomimetic agents (pilocarpine, echothiophate) | “20%–25%” |
| Rho kinase inhibitors (netarsudil) | “10%–20%” |
| Topical carbonic anhydrase inhibitors (brinzolamide, dorzolamide) | “15%–20%” |
| Oral carbonic anhydrase inhibitors (acetazolamide, methazolamide) | “20%–30%” |
Adding medications: incremental IOP reduction
European Glaucoma Society guidelines: switching and fixed combinations
NICE NG81: escalation to another therapeutic class
Intracameral sustained-release implants
Summary: approved intracameral prostaglandin implants as comparators
Two intracameral prostaglandin implants are FDA approved for IOP reduction in OAG or OHT. The bimatoprost 10 mcg biodegradable implant (Durysta) is labeled for a single administration per eye without retreatment because of corneal endothelial cell loss. In the ARTEMIS 1 (3 arms of 198 participants) and ARTEMIS 2 (528 participants) phase 3 trials, the implant was noninferior to twice-daily timolol through week 12; in ARTEMIS 1, with 3 administrations at fixed 16-week intervals, 10.2% of eyes (10 mcg) and 21.8% (15 mcg) had 20% or greater endothelial cell density loss. In the phase 3b TRITON study (441 participants), median time to retreatment or rescue after a single implant was 392 days. The travoprost 75 mcg titanium implant (iDose TR) is anchored in the sclera at the iridocorneal angle; in 2 phase 3 trials (1,150 participants pooled), it was noninferior to timolol over the first 3 months, and at month 12, 81.4% of slow-eluting implant eyes were free of topical IOP-lowering medication. Its current label notes that noninferiority was not demonstrated over the subsequent 9 months and permits readministration no more than once per year, with removal of the previous implant. Both implants are administered as separate intracameral procedures, whereas the investigational BIM-IOL System is placed in the capsular bag during cataract surgery.
AAO Preferred Practice Pattern: sustained drug delivery within medical therapy
European Glaucoma Society guidelines: availability in Europe
Bimatoprost intracameral implant: labeled administration limit
Bimatoprost implant pivotal trial ARTEMIS 1: efficacy and corneal safety
“Study eyes received bimatoprost implant 10 μg (n = 198) or 15 μg (n = 198) on day 1 with readministration at weeks 16 and 32, or twice-daily topical timolol maleate 0.5% (n = 198).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Both dose strengths of bimatoprost implant were noninferior to timolol in IOP lowering after each administration.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Incidence of corneal TEAEs increased after repeated treatment; with 3 administrations at fixed 16-week intervals, incidence of ≥20% CECD loss was 10.2% (10-μg implant) and 21.8% (15-μg implant).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Bimatoprost implant pivotal trial ARTEMIS 2: efficacy and treatment-free probability
“This randomized, 20-month, multicenter, masked, parallel-group, phase 3 trial enrolled 528 patients with OAG or OHT and an open iridocorneal angle inferiorly in the study eye.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean IOP reductions from baseline ranged from 6.2-7.4, 6.5-7.8, and 6.1-6.7 mmHg through week 12 in the 10 µg implant, 15 µg implant, and timolol groups, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Probabilities of requiring no IOP-lowering treatment for 1 year after the third administration were 77.5% (10 µg implant) and 79.0% (15 µg implant).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bimatoprost implant phase 3b TRITON: duration after a single administration
“In total, 441 patients received the 10-µg bimatoprost implant in the study eye on day 1 (cycle 1), 179 patients received a second administration (cycle 2), and 378 patients had at least 12 months of follow-up data available. The median time (95% confidence interval) from the first administration to a second administration or rescue was 392 (369, 485) days; the probability of not requiring retreatment or rescue by day 360 was 57.5%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bimatoprost implant versus SLT: ATHENA paired-eye trial
“The probability of not having required nonstudy (rescue) IOP-lowering treatment at days 360 and 720, respectively, was 67.5% and 50.2% for implant-treated eyes versus 68.7% and 60.6% for SLT-treated eyes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean (±SE) percentage change in corneal endothelial cell density from baseline at month 24 was -6.2 ± 1.13% in implant-treated eyes (-7.9 ± 2.04% with fixed readministration; -5.2 ± 1.35% with flexible readministration) versus -3.1 ± 0.43% in SLT-treated eyes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Travoprost intracameral implant: label indication, efficacy, and readministration
Travoprost implant pivotal trial GC-010: 3-month primary endpoint
“Study eyes were randomized to the travoprost intraocular implant (FE implant [n = 200] or SE implant [n = 197] model) or to timolol ophthalmic solution 0.5% twice daily (n = 193).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean IOP reduction from baseline over the 6 time points ranged from 6.6 to 8.4 mmHg for the FE implant group, from 6.6 to 8.5 mmHg for the SE implant group, and from 6.5 to 7.7 mmHg for the timolol group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Study eye AEs, most of mild or moderate severity, were reported in 21.5%, 27.2%, and 10.8% of patients in the FE implant, SE implant, and timolol groups, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Travoprost implant: pooled 12-month analysis of two phase 3 trials
“A total of 1150 subjects were randomized (385 FE implant, 380 SE implant, and 385 sham/timolol) across the two trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With regards to reduction in topical pharmacotherapy, at month 12, 77.6% of FE and 81.4% of SE implant eyes were completely free of all topical IOP-lowering medications” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common TEAEs related to study treatment were hyperemia (conjunctival or ocular), iritis, and IOP increased.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Travoprost implant pivotal trial GC-010: 12-month results
“A total of 590 patients were enrolled at 45 sites and randomized to one of three treatment groups: 197 SE-implant (the intended commercial product), 200 FE-implant, and 193 timolol.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The SE-implant was non-inferior to timolol eye drops in IOP lowering over the first 3 months, and was also non-inferior to timolol at months 6, 9, and 12.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Bimatoprost implant pivotal trial: noninferiority margin and primary analysis population
“Analysis of IOP change from baseline used a similar MMRM approach with IOP hour-matched change from baseline as the response variable, and noninferiority was to be declared if the 95% CI of the between-group difference was within a 1.5-mmHg noninferiority margin at both hours 0 and 2 at week 12.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The primary analyses of IOP used observed values in the intent-to-treat population of all randomized subjects.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Bimatoprost implant pivotal trial: corneal adverse events rose with each repeated administration
“Although most TEAEs showed generally similar incidence rates after the first, second, and third implant administration, corneal TEAEs of interest occurred more frequently after repeated treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, the rate of corneal TEAEs of interest (but not other TEAEs) increased with each subsequent administration. These findings suggest that the events likely occurred secondary to a physical interaction between the implant(s) and the cornea.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Because 3 implants were administered at fixed 4-month treatment intervals, the slow biodegradation allowed as many as 3 implants to be present at the same time in some eyes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Bimatoprost implant pivotal trial: corneal events attributed to implant accumulation in the iridocorneal angle
“Comparison of findings from the phase 1/2 and phase 3 studies suggests that when more implants occupy the inferior angle in a short period of time, there is greater potential for endothelial cell contact and loss.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, the occurrence of corneal events in some subjects appeared to be related to accumulation of implant material in the iridocorneal angle, and these corneal events may have been abated with less frequent administration.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Bimatoprost implant pivotal trial: implant removal for corneal adverse events
“Implant removal should be avoided when possible because of the increased risk of adverse events associated with intraocular procedures, such as endophthalmitis, iritis, and lens and corneal damage.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We observed that in general, corneal TEAEs resolved after implant removal, and CECD stabilized in subjects who had undergone corneal endothelial cell loss.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Bimatoprost implant versus laser trabeculoplasty: noninferiority margins applied
“the upper limit of the 95% CI for the between-group difference (bimatoprost implant minus SLT) was within the statistical and clinical noninferiority margins (1.5 mm Hg and 1.0 mm Hg, respectively) at all 3 timepoints, demonstrating statistical and clinical noninferiority of the bimatoprost implant to SLT” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Bimatoprost implant versus laser trabeculoplasty: endothelial cell loss by administration schedule and angle width
“Among eyes treated with the bimatoprost implant, ≥20% ECL was observed in 9.0% of eyes on the fixed administration schedule and 7.1% of eyes on the flexible administration schedule” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of ≥20% ECL with the flexible administration schedule of bimatoprost implant versus SLT was 4.9% versus 4.0% in eyes with Shaffer grade 4 angles and 9.1% versus 2.6% in eyes with Shaffer grade 3 angles.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Results of this study indicate that the risk of corneal events and ECL associated with bimatoprost implant treatment can be lessened by using the implant in eyes with wide open (Shaffer grade 4) angles.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Bimatoprost implant versus laser trabeculoplasty: proposed mechanism of endothelial loss and effect on visual acuity
“The most important safety concern with the bimatoprost implant is ECL, which has been proposed to result from physical interactions between the implant(s) and the cornea, and to be more frequent after multiple implants are administered because of slow biodegradation of the polymer and accumulation of residual implant.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Within the subgroup of implant-treated eyes with a reported ≥20% loss in CECD, 7 eyes had a ≥ 3-line loss in BCVA.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Travoprost implant phase 3 trial: noninferiority margin, observed confidence intervals, and planned sample size
“The maximal mean difference in IOP change from baseline across all 6 time points was 0.10 mmHg (with an upper 95% CI of 0.83 mmHg) for the FE implant versus timolol groups and 0.10 mmHg (with an upper 95% CI of 0.82 mmHg) for the SE implant versus timolol groups. Therefore, the criteria for statistical and clinical noninferiority to timolol was met for both implant groups because the upper limit of the 95% CI of the difference between the implant groups and the timolol group was < 1.5 mmHg and also < 1 mmHg for all 6 time points” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“With a true mean difference of 0, 85% power to declare noninferiority for at least 1 implant group over the timolol group would be achieved with 186 patients per treatment group or 558 patients overall.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Travoprost implant phase 3 trial: extent of corneal endothelial cell monitoring
Travoprost implant 12-month report: status of the month 6, 9, and 12 noninferiority analyses
“After the phase 3 trial was initiated, but prior to the database lock and unmasking, a 12-month non-inferiority comparison to timolol was included as a secondary endpoint based on regulatory agency guidance; however, the trial was not prospectively powered for the noninferiority comparison at 12 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A second limitation is that the non-inferiority analyses for the month 6 and 9 visits were not prospectively defined. However, the analyses used the same definition as for month 12. A third limitation of the study is that the trial was not prospectively powered for the 6, 9, and 12-month IOP efficacy evaluations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At months 6 and 9 (visits at which IOP was measured at 8 A.M., 10 A.M., or 4 P.M. and used time-matched baseline), non-inferiority to timolol was demonstrated for both implant groups using the same definition as used for month 12” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Travoprost implant 12-month report: intraocular pressure reduction by visit and change in medication burden
“IOP reductions with the to-be-marketed SE-implant ranged from 6.6 to 8.5 mmHg at the primary efficacy endpoint (8 A.M. and 10 A.M. at day 10, week 6, and month 3) used for application of regulatory approval in the USA. At months 6 and 9, when IOP was measured at 8 A.M., 10 A.M., or 4 P.M., IOP reductions were 5.7 mmHg at both visits, while at month 12, when IOP was measured at 8 A.M. and 10 A.M., IOP reductions were 5.5 mmHg at both timepoints, with non-inferiority of the SE-implant to timolol being demonstrated over the entire 12 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, in the current trial, of those patients who were on glaucoma medication at screening, 83.5% of patients in the SE-implant group versus only 23.9% of patients in the timolol group were well controlled on fewer topical medications at month 12 compared to screening.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Travoprost implant 12-month report: completion and discontinuation through month 12
Laser trabeculoplasty
AAO Preferred Practice Pattern: initial or adjunctive laser therapy
European Glaucoma Society guidelines: first-line option
NICE NG81: 360° SLT as initial treatment
LiGHT trial: 3-year results
“Of 718 patients enrolled, 356 were randomised to the selective laser trabeculoplasty and 362 to the eye drops group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 36 months, 74·2% (95% CI 69·3-78·6) of patients in the selective laser trabeculoplasty group required no drops to maintain intraocular pressure at target.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
LiGHT trial: 6-year results
“Of eyes in the SLT arm, 69.8% remained at or less than the target IOP without the need for medical or surgical treatment. More eyes in the drops arm exhibited disease progression (26.8% vs. 19.6%, respectively; P = 0.006). Trabeculectomy was required in 32 eyes in the drops arm compared with 13 eyes in the SLT arm (P < 0.001); more cataract surgeries occurred in the drops arm (95 compared with 57 eyes; P = 0.03). No serious laser-related adverse events occurred.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
LiGHT: drop-free intraocular pressure control and medication use in both arms at 6 years
“Drop-free IOP control at 72 months, obtained without incisional surgery, was achieved in 69.8% of eyes initially treated with SLT compared with 18.0% of eyes initially treated with IOP-lowering eye drops.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At 72 months, 61.2% of eyes initially treated with eye drops were using 1 or 2 medications compared with 18.5% of eyes initially treated with SLT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of the eyes initially treated with eye drops and being drop free at 72 months, 79.5% of eyes (66 eyes) had switched to SLT, and 20.5% underwent either cataract surgery alone or cataract surgery and SLT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
LiGHT: eyes at target intraocular pressure and number of laser treatments required
“Overall, 94.2% of eyes initially treated with SLT were at target at 72 months, and target IOP was achieved at 92.8% of visits, compared with 94.7% of eyes and 93.2% of visits for eyes initially treated with medication.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of the eyes initially treated with SLT and being drop and surgery free at 6 years, 90% of eyes (295 eyes) needed up to 2 SLT treatments in total.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
LiGHT: adverse events of selective laser trabeculoplasty over 6 years
“A total of 274 transient SLT-related adverse events were reported, including 10 incidents of a rise in IOP (1.0% of all SLT treatments, with only 1 eye requiring treatment).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The safety profile of SLT remains very good, with no sight-threatening complications.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Intraocular pressure rose > 5 mmHg from IOP before treatment in only 1% of treated eyes, and of these, only 1 eye needed treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
LiGHT: timing of trabeculectomy during the 6-year trial
“Of the 32 eyes that needed a trabeculectomy during trial’s 6-year duration, 11 eyes initially treated with drops underwent a trabeculectomy during the first 3 years of the trial; none of the eyes initially treated with SLT required a trabeculectomy during the initial 3 years of the trial.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Minimally invasive and incisional glaucoma surgery
AAO Preferred Practice Pattern: MIGS compared with traditional surgery
European Glaucoma Society guidelines: MIGS indications and contraindications
Overview of Cochrane reviews of MIGS
“Moderate certainty evidence indicated that adding a Hydrus safely improved the likelihood of drop-free glaucoma control at medium-term (relative risk [RR], 1.6; 95% CI, 1.4 to 1.8) and long-term (RR, 1.6; 95% CI, 1.4 to 1.9) follow-up and conferred 2.0-mm Hg (95% CI, -2.7 to -1.3 mm Hg) greater IOP reduction at long-term follow-up, compared with cataract surgery alone. Adding an iStent also safely improved drop-free disease control compared with cataract surgery alone (RR, 1.4; 95% CI, 1.2 to 1.6), but the short-term IOP-lowering effect of the iStent was not sustained.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Trabeculectomy: AAO Preferred Practice Pattern
TAGS: primary trabeculectomy versus medication in advanced glaucoma, 5 years
“The mean IOPs were 12.07 ± 5.18 mmHg and 14.76 ± 4.14 mmHg, respectively, and the mean difference was -2.56 (95% CI, -3.80 to -1.32; P < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 5 years, the Treatment of Advanced Glaucoma Study demonstrated that primary trabeculectomy surgery is more effective in lowering IOP and preventing disease progression than primary medical treatment in patients with advanced disease and has a similar safety profile.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PTVT: tube shunt versus trabeculectomy, 5 years
Combined cataract and glaucoma surgery
AAO Preferred Practice Pattern: options for patients with POAG and visually significant cataract
European Glaucoma Society guidelines: mild to moderate glaucoma with cataract
Cataract extraction in the OHTS observation group
“In the cataract group, postoperative IOP was significantly lower than the preoperative IOP (19.8 ± 3.2 mmHg vs. 23.9 ± 3.2 p<0.001). The postoperative IOP remained lower than preoperative IOP for at least 36 months. The average decrease in postoperative IOP from preoperative IOP was 16.5%, and 39.7% of eyes had postoperative IOP ≥ 20% below preoperative IOP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
HORIZON: Hydrus Microstent with cataract surgery, 5 years
“Three hundred sixty-nine eyes were randomized to HMS treatment, and 187 eyes were randomized to CS only.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The number of glaucoma medications was 0.5 ± 0.9 in the HMS group and 0.9 ± 0.9 in the CS group (P < 0.001), and 66% of eyes in the HMS group were medication free compared with 46% in the CS group (P < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
iStent inject pivotal trial with cataract surgery, 2 years
“At 24 months, 75.8% of treatment eyes versus 61.9% of control eyes experienced ≥20% reduction from baseline in unmedicated DIOP (P = 0.005), and mean reduction in unmedicated DIOP from baseline was greater in treatment eyes (7.0±4.0 mmHg) than in control eyes (5.4±3.7 mmHg; P < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HORIZON: secondary intraocular pressure-lowering procedures through 5 years
“Twenty-two events occurred in 18 eyes (4.9%) in the HMS group, and 30 events occurred in 14 eyes (7.5%) in the CS group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A finding of particular interest in this study is that, among a cohort of patients with predominantly mild glaucoma that was controlled with 1 or 2 topical medications, a significant proportion needed invasive glaucoma surgery over 5 years, particularly in the CS group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HORIZON: medication count from 1 to 5 years after surgery
HORIZON: visual acuity and visual field adverse findings through 5 years
“After 5 years, cumulative BCVA loss of 2 lines or more was 1.9% in the HMS group and 2.1% in the CS group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A loss of 2.5 dB or more in VF mean deviation was defined as an adverse finding in the protocol.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This condition was met in 8.4% of HMS eyes and 9.6% of CS eyes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HORIZON: corneal endothelial cell loss through 5 years
“The authors observed an ECL of 13% and 11% in the HMS and CS groups, respectively, at the first postoperative assessment performed at 3 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, no shift toward increased ECL was found in years 4 or 5 compared with prior years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“None of the eyes with 30% or more ECL in either group had associated corneal edema, decompensation, or other clinical sequelae.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HORIZON: medication washout schedule and its effect on later pressure comparisons
“The medication washout requirement enabled a direct assessment of the device alone on IOP not confounded by medication use but simultaneously limited the population to patients with mild and moderate severity of disease who could tolerate the washout procedure safely.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, medication washout was not repeated after 2 years; thus, the possibility of medication introduction bias must be considered for later IOP assessments.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
iStent inject pivotal trial: medication burden and drop-free proportion at 23 months
“In the treatment group, the mean number of ocular hypotensive medications was 1.6 (SD, 0.8) preoperatively and 0.4 (SD, 0.8) at 23 months, a mean reduction of 1.2 medications (SD, 1.0; P < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In this study, 84% of treatment eyes meeting the primary study end point were not taking ocular hypotensive medications at 23 months, compared with 67% of control eyes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
iStent inject pivotal trial: washout design and medication-free proportions at 6 and 12 months
“At the month 11 and 23 visits, subjects using ocular hypotensive medication(s) were instructed to undergo medication washout to permit unmedicated DIOP assessment at months 12 and 24, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Eyes with secondary surgical interventions to lower IOP or other events (including loss of light perception or hypotony (IOP <6 mmHg) associated with clinically significant findings) were considered nonresponders.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At 6 months, 81.4% of treatment subjects versus 64.1% required no additional medications or surgeries; in these subjects, mean IOP reduction was 9.2 mmHg in the treatment group and 8.2 mmHg in the control group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
iStent inject pivotal trial: intraocular pressure in medication-free eyes from 6 to 24 months
iStent inject pivotal trial: visual field and cup-to-disc stability through 24 months
“Visual field MD was stable over time (mean change close to zero) from screening to 24 months in both groups.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean C:D ratio also was stable over time from screening to month 24 in both groups.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
iStent inject pivotal trial: endothelial cell loss through 24 months
“There was little difference in endothelial cell loss (ECL) between the treatment and control groups.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The percentage of eyes with an ECL >30% at the 24-month visit was similar between the 2 groups (10.4% in the iStent inject group vs. 9.5% in the control group).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In both study groups, the most substantial decline in ECD occurred within the first 3 months postoperatively (12.5% in the iStent inject group and 11.6% in the control group), and the rate of decline was minimal thereafter.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Visual field progression after cataract surgery with a microstent compared with cataract surgery alone
“In the HORIZON trial, the rate of VF progression was significantly slower in eyes that received cataract surgery in combination with the Hydrus microstent compared with the control group receiving only cataract surgery, despite similar medicated IOP in both arms.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of current therapies
Summary
Topical therapy depends on daily self-administration. A 2025 meta-analysis of 47 studies (961,000 patients) estimated that 44% of patients on prostaglandin analogs were adherent at year 1 and that persistence fell from 75% at month 6 to 31% at year 3; in a claims cohort of 3,623 patients with diagnosed glaucoma and 1,677 suspects, nearly one half discontinued all topical therapy within 6 months. The AAO guideline cites a study in which nearly 45% of patients took fewer than 75% of prescribed doses despite free medication, dosing aids, and electronic monitoring. In the CIGTS medication arm (307 participants), predicted 8-year mean deviation loss was 0.62 dB with no reported missed doses and 2.23 dB with missed doses at two thirds of visits. Drop instillation is frequently incorrect: 6 of 70 patients (8.57%) instilled drops correctly in one study, and 33.8% of 500 Canadian patients demonstrated improper technique. Ocular surface disease symptoms were reported by 305 of 630 patients (48.4%) using topical therapy, with higher scores as the number of medications increased. Among procedural alternatives, SLT effect may wane and require repetition, MIGS are indicated mainly for mild to moderate disease and are performed routinely by about one third of US cataract surgeons (company estimate), incisional surgery carries higher complication risk, and approved intracameral implants carry corneal endothelial cell loss warnings and administration limits.
Adherence and persistence with prostaglandin analogs: systematic review and meta-analysis
“The SLR included 50 publications reporting on 47 unique studies and involving 961,000 patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean proportion of patients on any/unspecified PGA who were adherent at Year 1 was 44% (95% CI: 31%-58%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean proportion of patients on any/unspecified PGA who were persistent fell from 75% (95% CI: 66%-85%) at Month 6 to 31% (95% CI: 12%-55%) at Year 3” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Persistence with topical therapy: US claims cohort
“Nearly one half of the individuals who had filled a glaucoma prescription discontinued all topical ocular hypotensive therapy within six months, and just 37% of these individuals recently had refilled their initial medication at three years after the first dispensing.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Adherence measured by pharmacy claims: GAPS
“The mean medication possession ratio (MPR) was 0.64 (median 0.57) for the 13,956 subjects. Although 59% potentially had an ocular hypotensive agent at 12 months, only 10% had such medication available continuously.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
AAO Preferred Practice Pattern: adherence and instillation barriers
Nonadherence and visual field loss: CIGTS medication arm
“Worse medication adherence was associated with loss of MD over time (p=0.005). For subjects who reported never missing a dose of medication, the average predicted MD loss over 8 years was 0.62 dB, consistent with age-related loss (95% confidence interval, CI=0.17−1.06; p=0.007); subjects reporting missing medication doses at 1/3 of visits had a loss of 1.42 dB (CI, 0.86−1.98; p<0.0001); subjects reporting missing medication doses at 2/3 of visits had a loss of 2.23 dB (CI, 1.19−3.26; p<0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacy refill adherence, IOP, and structural and functional progression
“A total of 13 670 eyes from 8163 patients were included with a median (interquartile range) PDC of 60 (40.9-77.5). Below the 60% adherence threshold (median), each 10% decrease in PDC was associated with higher mean IOP (β = 0.82 mmHg, P < 0.001)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Barriers to adherence: cross-sectional survey
“27% of the sample reported poor adherence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Logistic regression analysis, adjusted for age, revealed that the following barriers were associated with higher odds of non-adherence: decreased self-efficacy, OR = 4.7 [95% CI 2.2–9.7, p= < 0.0001]; difficulty instilling drops, OR = 2.3 [95% CI 1.1–4.9, p= 0.03]; forgetfulness, OR = 5.6 [95% CI 2.6–12.1, p= < 0.0001]; and difficulties with the medication schedule, OR = 2.9 [1.4–6.0, p= 0.006].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Drop instillation errors
“Only 6 patients (8.57%) were able to correctly instill the eye drops (squeeze out 1 drop and instill it into the conjunctival sac without bottle tip contact).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Nearly, 9 of 10 glaucoma patients were unable to instill eye drops correctly.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“500 patients from 10 centers across Canada participated in the study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“With regard to drop administration, 6.8% missed their eye and 28.8% contaminated the bottle tip; overall, 33.8% demonstrated improper technique.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ocular surface disease with topical therapy
“Overall, 630 patients from 10 sites participated. Of these, 305 patients (48.4%) had an OSDI score indicating either mild (n = 134, 21.3%), moderate (n = 84, 13.3%), or severe (n = 87, 13.8%) OSD symptoms.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The severity of OSD symptoms is positively correlated to the number of IOP-lowering medications used.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Using Ocular Surface Disease Index for measuring symptoms of dry eye, 60 (59%) patients reported symptoms in at least 1 eye.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“After adjustment for age and sex, each additional BAK-containing eyedrop was associated with an approximately 2 times higher odds of showing abnormal results on the lissamine green staining test (odds ratio=2.03; 95% confidence interval: 1.06 to 3.89; P=0.034).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
European Glaucoma Society guidelines: preservatives and ocular surface disease
Procedural limitations: MIGS uptake and intracameral implants (manufacturer perspective)
Laser trabeculoplasty: waning effect and IOP spikes
Traditional incisional surgery: complication risk
Medication possession ratio on prostaglandin analogs relative to the threshold for good adherence
“The mean MPR/PDC of 54% at Year 1 in this review was similar to that reported in Reardon et al (mean MPR/PDC: 56%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Both values (54% and 56%) were below the 80% threshold for good adherence” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Definition of persistence and pattern of decline, including by individual prostaglandin analog
“In the measurement of persistence, persistent patients were defined as those who did not switch or discontinue their therapies, with an allowable refill gap of up to 90 days. Duration of therapy was defined as the period between initial therapy prescription and therapy discontinuation or switch.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The estimated persistence rates over time for patients on PGAs in our MA suggest that in real-world settings, persistence among patients initiating PGA monotherapy is likely to substantially decline within three years, with the fastest rates of discontinuation occurring in the first 6 to 12 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients on latanoprost were more likely to be persistent at each of the timepoints analyzed compared with patients on travoprost or bimatoprost.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, the CIs of the persistence rates of patients on travoprost, bimatoprost and latanoprost in this review overlapped substantially, suggesting that differences between the individual PGAs were not statistically or clinically significant.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Agreement between self-reported adherence and electronically monitored adherence
“Two studies evaluated differences between patient-reported adherence (using the MMAS) and adherence as measured using electronic dose monitoring devices, with both studies reporting low agreement between them. Patients tended to report themselves as more adherent than the objective measures recorded.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Adherence at three years by drug class in a United States claims cohort
“A total of 3623 patients with diagnosed glaucoma and 1677 patients with suspect glaucoma filled at least one prescription for topical ocular hypotensive agents.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“With a definition for adherence that allows individuals to intermittently refill prescriptions (which means medications are taken substantially less than prescribed), only 37% of patients had refilled their initially prescribed medication within 60 to 120 days at 3 years after their initial dispensing. Adherence estimates at 3 years ranged from 15% to 58%, depending on drug class.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Direction of bias in claims-based persistence estimates
“We have assumed a liberal duration for each dispensing on the basis of bottle sizes. It is likely therefore that even the very low estimates of persistence and adherence that we found were overestimations of the true levels.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Successful glaucoma surgery or laser treatment may have obviated the need for further topical therapy in some patients, but the occurrence of such treatments was rare in this population (approximately 5% had surgery or laser treatment at any time during the follow-up period) and cannot account for the low persistence estimates that we have observed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
One-year refill patterns: gaps, restarts, switches, and discontinuation
“Among 10,260 subjects who were followed up for at least 1 year after the index prescription, to measure persistency as a function of gaps between refills, 10% used the originally prescribed prostaglandin without any gaps in refilling the prescription, 8% as monotherapy, and 2% with a second drug added to their regimen.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Sixteen percent switched from the index drug to another drug, and 20% discontinued all glaucoma medications without adding, switching, or restarting.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“More than 55% of the patients who had at least 1 year of follow-up, failed to continuously refill their initial medications for a period and later restarted it.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In this study, a survival analysis would have identified 90% as failing to refill medications continuously over the study period.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Effect of free samples on measured adherence
“One fifth of subjects (20%) reported receiving samples on a regular basis, 57% received samples one or two times, and 23% reported never receiving samples. The mean MPRs for these three groups were 0.62, 0.64, and 0.76, respectively” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of noncompliance and of combined noncompliance or improper technique
“Of these, 25.6% reported missing at least 1 drop of medication per week, and 4.2% were unable to accurately describe their medication regimen. The overall proportion of noncompliance was 27.9%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Over 50% of the patients surveyed were either noncompliant or demonstrated improper administration technique.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Observed instillation technique and waiting interval between medications
“Four hundred and seventy-three patients demonstrated their eye drop administration technique. Of those, 365 (77.2%) were judged to be “on target,” 76 (16.1%) were “awkward,” and 32 (6.8%) “missed the eye,” while 136 (28.8%) patients contaminated the bottle tip.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, of the 296 patients who required more than 1 type of medication in the same eye, 26 (8.8%; 95% CI 5.8%–12.6%) reported waiting less than 3 minutes between administrations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Reasons for missed doses and receipt of instillation instruction
““Forgetfulness” (35.4%) and “being away from drops” (31.1%) were the most common reasons indicated.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In our current study only 19.1% of patients had received instructions on ophthalmic medication administration from their pharmacist” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Place in treatment, anticipated use, and care setting
Summary
The BIM-IOL System is investigational and has no guideline-defined place in therapy. Its studied use is a single implantation during routine cataract surgery, placed in the capsular bag, in adults with mild to moderate OAG or OHT and a concomitant cataract. The phase 3 trials SGP-005 (Rhine) and SGP-006 (Rhone), each planned for about 400 participants, enroll patients taking up to two IOP-lowering medications and compare the 78 mcg system with a commercial monofocal IOL plus twice-daily timolol. Guidelines currently offer patients with glaucoma and cataract whose IOP is at or near target on one or two medications cataract surgery alone or cataract surgery with MIGS; the BIM-IOL System would be an additional option in this setting, and the manufacturer positions it for surgeons who do not perform angle-based MIGS. The AAO guideline states that sustained medication delivery methods may be better options for patients who find drop administration very difficult. The manufacturer designs the pads to deliver bimatoprost for about 3 years; retreatment would require the separate investigational BIM-DRS. Cataract surgery in the United States is performed mainly in ambulatory surgery centers (manufacturer estimate about 90%), and a Category III add-on CPT code was approved in May 2026 for use with cataract surgery codes. The manufacturer estimates about one million US cataract surgeries per year in patients with glaucoma or OHT. Cataract surgery alone lowered IOP by 16.5% in the OHTS observation group, and no comparison of the BIM-IOL System with cataract surgery alone or with MIGS combined with cataract surgery is available.
Anticipated use: implantation during routine cataract surgery
Studied population: phase 3 registrational trials
Studied population: registry eligibility for the Rhine trial
Duration of therapy and retreatment pathway
Guideline setting for combined treatment at cataract surgery
Angle-sparing placement and compatibility with later procedures
“First, the implantation of the system is highly accessible to all surgeons who routinely perform CEIOL procedures. Second, it leaves the angle untouched, allowing for concurrent or subsequent gonioscopic intervention, or subsequent selective laser trabeculoplasty. Third, the positioning of the system within the capsular bag may limit mechanical injury to the corneal endothelium.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Care setting and reimbursement pathway
Anticipated population size (manufacturer estimate)
Heterogeneity of treatment effect
BIM-IOL System first-in-human study: no difference across 3 dose arms
“Each treatment arm realized mean IOP reductions from 32.3% to 49.3% over 3 years of follow-up visits. There were no significant intergroup differences.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Outcomes were not significantly different between low, medium, and high concentrations of sustained release bimatoprost. One may hypothesize that higher doses would correlate with more substantive IOP-lowering. However, this did not necessarily hold true in the current sample; the greatest IOP reduction from baseline to month 36 was achieved in the 75 μg cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
BIM-IOL System first-in-human study: limits on generalizability to nonresponders and other populations
“All subjects were required to have previously responded to topical prostaglandin analogues. This criterion selected for eyes that would be more likely to benefit from the bimatoprost implant, possibly inflating efficacy metrics. Generalizability to nonresponders is thus limited.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The single-site design with a sample comprised entirely of white Latino patients with POAG further limits generalizability to wider populations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most subjects required only a single glaucoma medication prior to washout; as such, it is less clear how this product would perform for more recalcitrant glaucomas.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
BIM-IOL System phase 1/2 trial: results by dose group at 12 months
Effect of baseline IOP on response to IOP-lowering treatment
Variation in optic nerve susceptibility and target IOP
EMGT: treatment effect across subgroups and baseline predictors of progression
“Treatment effects were also evident when stratifying patients by median IOP, mean deviation, and age as well as exfoliation status.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Predictive baseline factors were higher intraocular pressure (IOP) (ie, the higher the baseline IOP, the higher the risk), exfoliation, and having both eyes eligible (each of the latter 2 factors doubled the risk), as well as worse mean deviation and older age.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
AGIS: outcome of surgical sequence differed by race
LiGHT: visual field benefit of first-line SLT by severity
SLT responsiveness: features of nonresponsive eyes
“A subset of 27 eyes (15.0%) was identified as potentially nonresponsive and found distinctive with older age (mean [SD], 54.1 [12.5] years vs 44.2 [14.2] years; difference, 10.5 years; 95% CI, 2.9 to 18.1; P = .009), higher proportion of female participants (difference, 27.5%; 95% CI, 3.6 to 51.5; P = .03), and lower baseline IOP (difference, -3.2 mm Hg; 95% CI, -5.2 to -1.3; P = .001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subgroup efficacy results for the BIM-IOL System by race, disease severity, glaucoma subtype, or baseline IOP
No evidence found.
Medication-free rate after combined surgery varies with preoperative medication count
“Eyes requiring only a single medication for pressure control before surgery reached a higher rate of drop-free IOP control than eyes receiving multiple drops.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Even among eyes receiving maximum preoperative medical therapy (3 or 4 classes of medications), 59% were receiving fewer medications at 5 years, and 48% were completely medication free in the HMS group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
LiGHT: proportional visual field benefit across baseline severity groups
LiGHT: severity mix of the trial population
UKGTS: severity range and representativeness of the study population
“Furthermore, individuals with advanced open-angle glaucoma were excluded so that the results of the trial only apply to patients with mild to moderate glaucoma.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Because consecutive new patients were assessed and recruited for the UKGTS trial, the population studied was representative of the target population considered for treatment and on which the trial results will be applied.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Care management intervention strategies
AAO Preferred Practice Pattern: consensus follow-up intervals
AAO Preferred Practice Pattern: adherence assessment and education at each visit
European Glaucoma Society guidelines: identifying and improving nonadherence
NICE NG81: instillation technique and adherence checks
SEE program: personalized glaucoma coaching randomized trial
“Of 236 participants enrolled (108 in UM and 128 in HFHS), 235 (mean [SD] age, 67.3 [10.9] years; 124 [53%] female) were randomized to the SEE intervention (n = 117) or control (n = 118).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Medication adherence was significantly better in the SEE intervention group compared with that among control participants (mean [SD], 77.6% [19.7%]; n = 113 vs 58.0% [25.2%]; n = 114; difference, 19.7%; 95% CI, 13.7 to 25.6; P < .001), and more achieved 80% or greater adherence (62 of 113 [54.9%] vs 27 of 114 [23.7%]; P < .001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cochrane review of multifaceted behavioral adherence interventions
Corneal endothelial monitoring for intracameral implants
Care management programs specific to the BIM-IOL System
No evidence found.
Absence of a specular microscopy monitoring requirement for the bimatoprost implant
“Because of the large safety margin with a single implant, there is no regulatory requirement of specular microscopy monitoring in the bimatoprost implant prescribing information. Use of bimatoprost implant with multiple administrations would be off-label at the time of publication, and this is currently not recommended.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.
Expected outcomes of therapy
Summary
The goal of IOP-lowering therapy is to keep IOP within a target range that preserves optic nerve and visual field status and vision-related quality of life. The AAO guideline sets a reasonable initial goal of a 20% to 30% IOP reduction from baseline; the EGS guideline suggests at least 20% reduction (IOP 18 to 20 mmHg) in early glaucoma and at least 30% (15 to 17 mmHg) in moderate glaucoma. Randomized trials link IOP lowering to slower disease progression: in OHTS (1,636 participants), a 22.5% IOP reduction lowered 5-year conversion to POAG from 9.5% to 4.4% (hazard ratio 0.40); in EMGT (255 participants), a 25% reduction lowered progression from 62% to 45%, with about 10% lower progression risk per mmHg of initial reduction; in UKGTS (516 participants), latanoprost prolonged visual field preservation versus placebo (hazard ratio 0.44); and in AGIS, eyes with IOP below 18 mmHg at all visits had mean visual field change close to zero. For the BIM-IOL System, the phase 3 co-primary endpoints are time-matched mean IOP change from baseline through month 3 and best-corrected distance visual acuity of 20/40 or better. Reported company outcomes are a 34% mean IOP reduction with 98% of evaluable participants free of topical medication at 12 months (78 mcg, phase 1/2) and a 37% mean reduction with 95% drop-free at 36 months (first-in-human, 21 evaluable participants). Visual field preservation has not been reported for the BIM-IOL System.
AAO Preferred Practice Pattern: management goals and target IOP
European Glaucoma Society guidelines: setting the target IOP
OHTS: prevention of conversion from ocular hypertension to POAG
“During the course of the study, the mean +/- SD reduction in IOP in the medication group was 22.5% +/- 9.9%. The IOP declined by 4.0% +/- 11.6% in the observation group. At 60 months, the cumulative probability of developing POAG was 4.4% in the medication group and 9.5% in the observation group (hazard ratio, 0.40; 95% confidence interval, 0.27-0.59; P<.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
EMGT: IOP reduction and glaucoma progression
“On average, treatment reduced the IOP by 5.1 mm Hg or 25%, a reduction maintained throughout follow-up. Progression was less frequent in the treatment group (58/129; 45%) than in controls (78/126; 62%) (P =.007) and occurred significantly later in treated patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In multivariate analyses, progression risk was halved by treatment (HR = 0.50; 95% CI, 0.35-0.71).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Progression risk decreased by about 10% with each millimeter of mercury of IOP reduction from baseline to the first follow-up visit (HR = 0.90 per millimeter of mercury decrease; 95% CI, 0.86-0.94).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
EMGT long-term follow-up: immediate versus delayed treatment
“At study end, percentages of eyes with VI or blindness were slightly higher in the treated group than in the untreated control group, 12.1% vs 11.0%, and 9.4.% vs 6.1% respectively, as were subjects with VI in at least one eye, 19.5% vs 18.7%. The differences were not statistically significant, nor were cumulative incidences of VI in at least one eye.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
UKGTS: visual field preservation over 24 months
AGIS: sustained low IOP and visual field stability
“In the Associative Analysis, eyes with 100% of visits with intraocular pressure less than 18 mm Hg over 6 years had mean changes from baseline in visual field defect score close to zero during follow-up, whereas eyes with less than 50% of visits with intraocular pressure less than 18 mm Hg had an estimated worsening over follow-up of 0.63 units of visual field defect score (P =.083).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
LiGHT: 6-year rate of visual field progression with first-line SLT versus drops
BIM-IOL System reported outcomes to date
Visual field outcomes with the BIM-IOL System
No evidence found.
Target intraocular pressure and the proportion of visits at which it was met in the Ocular Hypertension Treatment Study
“Participants randomized to medication began treatment to achieve a target IOP of 24 mm Hg or less and a minimum 20% reduction in IOP from the average of the qualifying IOP and IOP at the baseline randomization visit, except that an IOP of less than 18 mm Hg was not required.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The IOP goal was met in both eyes at 87% (7515 of 8621) and in one eye at 7% (613 of 8621) of the scheduled follow-up visits completed by medication participants.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Visual field change per millimeter of mercury of intraocular pressure during early follow-up
“In the adjusted model 2 for all visits there is a predicted worsening in visual field defect score of 0.10 from baseline for each 1 mm Hg increase in average intraocular pressure, a finding that is statistically significant” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For example, an eye with intraocular pressure greater than 18 mm Hg at seven or more of twelve 6-month visits can expect, on average, a worsening of visual field defect score at 84 months that is approximately two units greater than an eye with intraocular pressure less than 18 mm Hg at each of these twelve 6-month visits” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A limitation of the present study and of previous studies of the association between intraocular pressure reduction and visual field damage is that the comparison between groups of eyes achieving low and high levels of intraocular pressure is not based on a random allocation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Mean intraocular pressure by proportion of visits below 18 mmHg and visual field change through 96 months
“The mean intraocular pressure over the first 6 years of follow-up is 12.3 mm Hg for group A, 14.7 mm Hg for group B, 16.9 mm Hg for group C, and 20.2 mm Hg for group D.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For group A (eyes presenting with intraocular pressure less than 18 mm Hg at each visit over 6 years), the mean changes in visual field defect score remain close to zero, whereas in each of the other three groups (B, C, and D), the mean change progressively increases over time to an average worsening in visual field defect score of about two to three points by 96 months” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Starting at 54 months, mean changes for the four groups diverge and remain consistently ranked according to the percent of visits with intraocular pressure less than 18 mm Hg.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Visual field loss in eyes maintained below 18 mmHg at every visit
“Although the average change in visual field is close to zero, a proportion of eyes in this group experienced visual field loss despite having intraocular pressure at what is believed to be a safe level.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“To illustrate, a worsening of four or more units of visual field defect score from baseline was experienced by 13.1% of eyes at 2 years, 13.9% at 5 years, and 14.4% at 7 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Basis for setting an individual target intraocular pressure and the usual size of reduction
“From a pathophysiological and therapeutic point of view, intraocular pressure is the primary modifiable risk factor, since progression of glaucoma usually stops if this pressure is lowered by 30–50% from baseline.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The target intraocular pressure for a particular eye is estimated based on the pretreatment intraocular pressure, the severity of damage, presence of risk factors for progression, life expectancy, and potential for adverse effects from treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The aim is usually for a reduction in intraocular pressure of 20–50%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Rate of visual field progression with immediate versus delayed treatment
“The median rate of progression was –0.14 dB/y slower in the treatment group in the eye with the worse rate (not statistically significant) and –0.10 dB/y slower in the eye with the better rate” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“As opposed to the results in terms of VI, these differences were consistently in favor of the group that received immediate treatment. The treatment group started out with worse MD values than the control group but ended up better.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
UKGTS: proportion of participants with visual field deterioration at 24 months
Mechanisms proposed for slower visual field progression with drop-independent treatment
“The exact mechanisms for this effect are still unclear and might be related to a more consistent control of IOP, a shorter time to achieve target pressure, and less reliance on patients’ compliance with treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Visual field outcome reporting in trials of first-line topical medications
“Not a single trial reported a difference or ratio between treatment groups with respect to visual field outcomes, although some trials provided group level data and treatment effect could be calculated based on the group level data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote